BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10763396)

  • 1. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):987-92. PubMed ID: 10763396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic burden of prostate cancer, California, 1998.
    Max W; Rice DP; Sung HY; Michel M; Breuer W; Zhang X
    Cancer; 2002 Jun; 94(11):2906-13. PubMed ID: 12115378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
    Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
    Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
    Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare costs associated with prostate cancer: estimates from a population-based study.
    Krahn MD; Zagorski B; Laporte A; Alibhai SM; Bremner KE; Tomlinson G; Warde P; Naglie G
    BJU Int; 2010 Feb; 105(3):338-46. PubMed ID: 19594734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of prostate cancer.
    Roehrborn CG; Black LK
    BJU Int; 2011 Sep; 108(6):806-13. PubMed ID: 21884356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
    Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
    Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
    Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime costs of colon and rectal cancer management in Canada.
    Maroun J; Ng E; Berthelot JM; Le Petit C; Dahrouge S; Flanagan WM; Walker H; Evans WK
    Chronic Dis Can; 2003; 24(4):91-101. PubMed ID: 14733758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An incidence model of the cost of advanced prostate cancer in Spain.
    Hart WM; Nazir J; Baskin-Bey E
    J Med Econ; 2014 Feb; 17(2):125-31. PubMed ID: 24350997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040.
    Waldeyer R; Brinks R; Rathmann W; Giani G; Icks A
    Diabet Med; 2013 Aug; 30(8):999-1008. PubMed ID: 23506452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
    Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
    Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.
    Crawford ED; Black L; Eaddy M; Kruep EJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):162-7. PubMed ID: 20125121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of obesity in Canada.
    Birmingham CL; Muller JL; Palepu A; Spinelli JJ; Anis AH
    CMAJ; 1999 Feb; 160(4):483-8. PubMed ID: 10081464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
    Reinhold T; Dornquast C; Börgermann C; Weißbach L
    Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenocarcinoma of the prostate: an expensive way to die.
    Piper NY; Kusada L; Lance R; Foley J; Moul J; Seay T
    Prostate Cancer Prostatic Dis; 2002; 5(2):164-6. PubMed ID: 12497008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic burden of prostate cancer - a Swedish prevalence-based register study.
    Hao S; Östensson E; Eklund M; Grönberg H; Nordström T; Heintz E; Clements M
    BMC Health Serv Res; 2020 May; 20(1):448. PubMed ID: 32434566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.